AzTrials
AzTrials

Health, SubjectiveLIFE-HOUSENCT04005456

Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design

A study testing Supplements and/or medical foods, Behavioral change support program and Food plan in people with Health, Subjective and Gastrointestinal Dysfunction, run by Metagenics, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The LIFE-HOUSE research project is designed to evaluate the impact of a personalized lifestyle intervention program on functional capacity as an approach to quantitating health, and its relationship to well understood disease risk determinants. LIFE-HOUSE will utilize an innovative Tent-Umbrella-Bucket design. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
What is being tested?
Supplements and/or medical foods, Behavioral change support program and Food plan
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteUnited States
Study dates
1 Sep 2018to 31 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

General Inclusion Criteria for 'N of 1' Tent:

  • male or female
  • ages 18-80, inclusive
  • willing to give written informed consent to participate in the study

General Exclusion Criteria for 'M of 1' Tent:

  • Medical History and Concurrent Diseases:
  • A serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic/rheumatological, or hematologic disease.
  • Known infection with HIV, TB or Hepatitis B or C.
  • Inability to comply with study and/or follow-up visits.
  • Any concurrent condition (including clinically significant abnormalities in medical history, physical examination or laboratory evaluations) which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.
  • Any sound medical, psychiatric and/or social reason which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.

The following describes specific inclusion and/or exclusion criteria applicable to individual study arms.

----------------------------------------------------------

Wellness Umbrella:

Specific Exclusion Criteria:

  • MOS SF-36 QN general score < 60

Elevated Homocysteine Bucket:

Specific Inclusion Criteria:

  • Elevated Homocysteine Level ≥ 10.4 µmol/L

Specific Exclusion Criteria:

  • MOS SF-36 QN general score < 60

Dental Health Umbrella:

Specific Inclusion Criteria:

  • Participants with extensive gingivitis/periodontitis/Caries/Painful teeth/Fractured Teeth. Identification of any of the following on physical exam: gingivitis, receding gumlines, periodontitis, fractured teeth, multiple unrestored caries. Identification on history of bleeding gums, bleeding while flossing, bleeding when brushing, chronic sores in the mouth, painful teeth, pain when biting on aluminum foil.

Neurological Health Umbrella:

Specific Inclusion Criteria:

  • Elevated score on any subscale of Depression Anxiety Stress Scale (DASS) QN; and/or a score demonstrating mild or moderate depression or anxiety on Beck Depression Score and Beck Anxiety Score; and/or a MOS SF-36 subscale Emotional Role Functioning or Mental Health < 50; and/or PROMIS Cognitive Function QN score < 50.

Autoimmune and Inflammatory Conditions Umbrella:

Specific Inclusion Criteria:

  • Symptoms, signs, laboratory biomarkers or diagnosis consistent with the features/diagnosis of an Autoimmune/Inflammatory Condition (excluding metabolic disorders/atherosclerosis) and ill-defined conditions characterized by symptomatic fatigue/myalgias.

Elevated ANA Bucket:

Specific Inclusion Criteria:

  • General Inclusion Criteria for Autoimmune and Inflammatory Conditions Umbrella
  • Elevated ANA Level > 1:40 titer (A specified sub-group for analysis will be all with two baseline elevated ANA Level > 1:40 titer.)

Specific Exclusion Criteria:

  • Symptoms, signs, laboratory biomarkers (excluding ANA) or diagnosis consistent with the features/diagnosis of an Autoimmune/Inflammatory Condition (excluding metabolic disorders/atherosclerosis)

Autoimmune Conditions Bucket:

Specific Inclusion Criteria:

  • Established Diagnosis of an autoimmune condition (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Bowel Disease and Hashimoto's Thyroiditis) with ANA level >1:80 titer, rheumatoid factor (RF) ≥ 14 IU/ml, fecal calprotectin ≥ 50 mcg/g and thyroid autoantibody levels specifically thyroglobulin antibodies ≥ 115 IU/ml and/or thyroid peroxidase antibodies ≥ 35 IU/ml.

Symptomatic Fatigue and Myalgia Bucket:

Specific Inclusion Criteria:

  • Two of the following five features have been generally present for at least 3 months:
  • Widespread bodily pain (pain in 3 of 5 regions (Left upper, right upper, left lower, right lower, axial) with and without symptomatic trigger points
  • Generalized fatigue
  • Sleep disturbances including awakening unrefreshed
  • Cognitive (memory or thought) problems
  • Post-exertional malaise

Gastrointestinal Health Umbrella:

Specific Inclusion Criteria:

  • Symptoms, signs, laboratory biomarkers or diagnosis consistent with the features/diagnosis of Irritable Bowel Syndrome and other GI symptomatology (excluding Inflammatory Bowel Disease) as well as physiological challenges with healthy detoxification

IBS Bucket:

Specific Inclusion Criteria:

  • Symptoms, signs, laboratory biomarkers or diagnosis consistent with the features/diagnosis of Irritable Bowel Syndrome and other GI symptomatology (excluding Inflammatory Bowel Disease)

Detoxification Bucket:

Specific Inclusion Criteria:

  • Symptoms, signs, laboratory biomarkers or diagnosis consistent physiological challenges with healthy detoxification

Wellness Detoxification Bucket:

Specific Inclusion Criteria:

  • Symptoms, signs, laboratory biomarkers or diagnosis consistent physiological challenges with healthy detoxification

Metabolic Health Umbrella:

Specific Inclusion Criteria:

  • BMI>= 18.5 and <40

Consequences of Metabolic Function/Dysfunction Bucket - Crossover Design:

Specific Inclusion Criteria:

  • BMI>= 18.5 and <40
  • Metabolic Dysfunction is defined as having at least two of the following: Glucose ≥ 100 mg/dl; Homeostatic Model of Assessment for Insulin Resistance (HOMA-IR) (Glucose [mg/dl]Insulin [µiu/L)/405), score ≥ 2.0; HbA1c ≥ 5.7%; Triglycerides ≥ 100 mg/dl; Low Density Lipoprotein Particle Number (LDLp) >1000, lipoprotein (a) (lp(a)) > 30 mg/dl ; HDL (women) ≤ 50 ng/ml; HDL (men) ≤ 40 ng/ml; and blood pressure ≥ 135/85 mm Hg.

Specific Exclusion Criteria:

  • Any of the following: Fasting Blood Glucose ≥ 125mg/dl; HbA1c ≥ 6.5% and Blood Pressure ≥ 165/95 mm Hg.

Consequences of Metabolic Function/Dysfunction Bucket - Randomization/Inclusion Design:

Specific Inclusion Criteria:

  • BMI>= 18.5 and <40
  • Metabolic Dysfunction is defined as having at least two of the following: Glucose ≥ 100 mg/dl; Homeostatic Model of Assessment for Insulin Resistance (HOMA-IR) (Glucose [mg/dl]Insulin [µiu/L)/405), score ≥ 2.0; HbA1c ≥ 5.7%; Triglycerides ≥ 100 mg/dl; Low Density Lipoprotein Particle Number (LDLp) >1000, lipoprotein (a) (lp(a)) > 30 mg/dl; HDL (women) ≤ 50 ng/ml; HDL (men) ≤ 40 ng/ml; and blood pressure ≥ 135/85 mm Hg

Specific Exclusion Criteria:

  • Any of the following: Fasting Blood Glucose ≥ 125mg/dl; HbA1c ≥ 6.5% and Blood Pressure ≥ 165/95 mm Hg.

Reproductive Health Umbrella:

Specific Inclusion Criteria:

  • Applicable to female Participants: a clinical diagnosis of fibrocystic breast and/or increased risk for Breast cancer, polycystic ovary syndrome, endometriosis, premenstrual syndrome, peri-menopause and menopausal conditions.
  • Applicable to male Participants: a diagnosis of testosterone deficiency and andropause/late onset hypogonadism or prostate health concerns.

Perimenopausal and Menopausal Transitions Bucket:

Specific Inclusion Criteria:

  • Female with signs/symptoms consistent with a clinical diagnosis of peri-menopause and menopausal conditions.

Premenstrual Syndrome Bucket:

Specific Inclusion Criteria:

  • Female with a diagnosis of premenstrual syndrome and/or signs/symptoms/biomarkers consistent with estrogen/progesterone imbalances.

PCOS Bucket:

Specific Inclusion Criteria:

  • Female with signs/symptoms/biomarkers consistent with a clinical diagnosis of PCOS.

Andropause/Late Onset Hypogonadism Bucket:

Specific Inclusion Criteria:

  • Male with signs/symptoms/biomarkers consistent with a clinical diagnosis of Andropause/Late Onset Hypogonadism.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Personalized Lifestyle Medicine Center

    Gig Harbor, Washington, 98332

Other trials in United States

About this study

Official title: LIFE-HOUSE: A Lifestyle Intervention and Functional Evaluation - a Health Outcomes Survey

The LIFE-HOUSE research project is designed to evaluate the impact of a personalized lifestyle intervention program on functional capacity as an approach to quantitating health, and its relationship to well understood disease risk determinants.

LIFE-HOUSE will utilize an innovative Tent-Umbrella-Bucket design.

Read more

Participants will gather under the Tent of an all-inclusive 'N of 1' Case Series providing a shelter of Functional Medicine interventions against the storm of chronic disease. Under this Tent are a collection of Umbrellas where participants with similar clinical challenges are evaluated as clinically defined groups with loose guidelines for the planned interventions. Finally, participants standing under these Umbrellas may step into specific Buckets that gather individuals with nearly identical clinical presentations into more formally described prescriptive randomized arms for intervention.

Individuals will be offered the opportunity to participate in all Umbrellas and Buckets for which they qualify. They may accept or reject participation in any Umbrella or Bucket and yet remain eligible for participation in the overall Tent.

Read the detailed description

It has been suggested that the best medicine should value four principles (4P) - medicine should be personalized, predictive, preventative and participatory. This 4P Medicine will thus be personalized and patient centered with a focus on the person who has the disease and not the disease the person has. It will be predictive as it identifies the pre-clinical trend/decline towards illness sooner than onset of symptoms that herald the loss of function and health. It will be preventative as the information gathered should offer opportunities to modify these trajectories towards illness and finally it will be participatory as individuals will be intimately involved in the gathering of data to identify trends and in the application of lifestyle measures to improve their lives.

There is a significant unmet need to identify the value of a personalized lifestyle intervention program for improving functional health outcomes. Whereas disease is well understood from traditional pathology-based indices, health is less easily defined. Historically, healthy has been the default term that is applied to an individual who is not recognized as having a disease. This definition of health as the absence of disease has resulted in the delivery of health and wellness as often lying outside the purview of medicine.

An evolving definition of health, however, is to recognize that it is related to the functional capacity of the individual. Functional capacity can be categorized in four assessment areas: physiological, physical, cognitive and emotional. All four of these subcategories are quantifiable by both qualitative and quantitative metrics. The effects on health of a multi-modal personalized lifestyle medicine intervention program can best be evaluated by using functional determinants.

Functional Medicine is an integrative medicine philosophy that uniquely incorporates 4P Medicine with a focus on function and dysfunction and the necessity to consider the physiological events that determine the balance between the two. The LIFE-HOUSE research project is designed to evaluate the impact of a personalized lifestyle intervention program on functional capacity as an approach to quantitating health, and its relationship to well understood disease risk determinants.

Individuals will be offered the opportunity to participate in all Umbrellas and Buckets for which they qualify. They may accept or reject participation in any Umbrella or Bucket and yet remain eligible for participation in the overall Tent. Due to the structure of the uniquely defined yet overlapping system of Umbrellas and Buckets, a specific Subject may participate consecutively and/or sequentially in a series of Umbrella and Buckets as applicable and their data may be included in multiple Umbrella and Bucket analyses.

Being tested
Supplements and/or medical foods, Behavioral change support program, Food plan
Keywords
wellness, n-of-1 trial, detoxification, personalized medicine, functional medicine, 4P medicine, lifestyle medicine, homocysteine, dietary supplement, medical food, behavioral change, lifestyle modification, employee wellness program, functional capacity, food plan
Medical subject headings
Autoimmune Diseases, Stomatognathic Diseases, Endocrine System Diseases, Cognition Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Supplements and/or medical foodsDietary supplement

    Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)

  • Behavioral change support programBehavioural

    Program to implement lifestyle and behavioral change according to individuals' need.

  • Food planOther

    Personalized food plan (e.g., basic wellness food plan, cardiometabolic food plan, high protein high phytonutrient food plan, ketogenic food plan, detoxification food plan, anti-inflammatory food plan, neuro food plan)

Study groups in NCT04005456
Study groupRoleWhat they receive
N of 1 TentOtherPersonalized dietary supplements, food plans, and behavioral change support program for a broad group (both an employee population and those recruited from practitioner practices) inclusive of all study Participants and specifically generally healthy individuals, those with established disease/conditions requiring a personalized approach, those with diseases/conditions currently with low prevalence in our study population and those women currently pregnant or breastfeeding.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Wellness UmbrellaOtherPersonalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals characterized by minimal physical complaints and laboratory biomarkers of modest clinical significance.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Elevated Homocysteine BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for individuals from the Wellness Umbrella with elevated homocysteine level ≥ 10.4 µmol/L.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Dental Health UmbrellaOtherPersonalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with established dental disease.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Immune Health UmbrellaOtherPersonalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with autoimmune/inflammatory conditions (excluding metabolic disorders/atherosclerosis)
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Elevated Anti-Nuclear Antibodies (ANA) BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of individuals with elevated levels of antinuclear antibodies (preclinical symptomatology only).
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Autoimmune Conditions BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of individuals with an established diagnosis of an autoimmune conditions (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Bowel Disease and Hashimoto's Thyroiditis) with ANA level >1:80 titer, rheumatoid factor (RF) ≥ 14 IU/ml, fecal calprotectin ≥ 50 mcg/g and thyroid autoantibody levels specifically thyroglobulin antibodies ≥ 115 IU/ml and/or thyroid peroxidase antibodies ≥ 35 IU/ml.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Symptomatic Fatigue/Myalgias BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a broad employee health group with symptoms of persistent fatigue and myalgias.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Gastrointestinal Health UmbrellaOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health and of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Irritable Bowel Syndrome (IBS) BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Detoxification BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Wellness Detoxification BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of individuals characterized by minimal physical complaints and normal biomarkers.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Metabolic Health UmbrellaOtherPersonalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia).
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Consequences of Metabolic (Dys)function Bucket C/S DesignOtherPersonalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). C/S = crossover
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Consequences of Metabolic (Dys)function Bucket R/I DesignOtherPersonalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). R/I = randomization/inclusion
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Ketogenic Product Development Exploratory GroupOtherSubgroup investigation in participants (classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia) during their 8- or 12-week ketogenic program intervention phase
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Reproductive Health UmbrellaOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of participants with conditions associated with reproductive and hormonal health (including polycystic ovary syndrome, premenstrual syndrome, endometriosis, peri-menopause and menopausal conditions, women currently pregnant or breastfeeding, testosterone deficiency and andropause/late onset hypogonadism, and prostate health).
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Perimenopausal and Menopausal Transitions BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically peri-menopause and menopausal conditions.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Premenstrual Syndrome BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically premenstrual syndrome.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Polycystic Ovary Syndrome (PCOS) BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of women with PCOS with signs/symptoms/biomarkers of both metabolic dysfunction and hormonal derangements.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan
Andropause/Late Onset Hypogonadism BucketOtherPersonalized dietary supplements, food plans, and behavioral change support program for a group of men with conditions associated with reproductive and hormonal health specifically testosterone deficiency and andropause/late onset hypogonadism.
Receives: Dietary Supplement: Supplements and/or medical foods; Behavioral: Behavioral change support program; Other: Food plan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Medical Outcomes Study Short Form 36 (MOS SF-36) questionnaire

    The MOS SF-36 is an indicator of overall health status. It has an eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability.

    Measured: Change from baseline at 12 months

  2. University of Rhode Island Change Assessment (URICA) questionnaire

    URICA questionnaire is a 32 item self-report measure that includes 4 subscales measuring the stages of change: Precontemplation, Contemplation, Action, and Maintenance (there is also a 24 item version). Responses are given on a 5 point Likert scale ranging from (1=strong disagreement to 5=strong agreement),

    Measured: Change from baseline at 12 months

  3. Depression Anxiety, Stress Scale (DASS) questionnaire

    The Depression, Anxiety and Stress Scale is a 21 items questionnaire that includes a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress. Outcome is divided into normal, mild, moderate, severe, and very severe for each of the 3 categories: Depression, Anxiety, and Stress. A low score represents the normal and the higher the score the more severe the outcome.

    Measured: Change from baseline at 12 months

Secondary outcomes (18)
  1. Body Mass Index (BMI)

    BMI is measured in (weight in kilogram (kg)/ height in meter (m)^2) outcome in double digits.

    Measured: Change from baseline at 12 months

  2. Waist Circumference (WC)

    WC is measured in centimeters (cm)

    Measured: Change from baseline at 12 months

  3. Hip Circumference (HC)

    HC is measured in cm

    Measured: Change from baseline at12 months

  4. Waist to Hip Ratio (WHR)

    WHR is numerical (0.00) and is and indicator for major health risk.

    Measured: Change from baseline at 12 months

  5. Height

    Height in meter (m)

    Measured: Change from baseline at 12 months

  6. Weight

    Weight in kilogram (kg)

    Measured: Change from baseline at12 months

  7. Glucose

    Fasting glucose levels measured in blood in milligram/deciLiter (mg/dL)

    Measured: Change from baseline at 12 months

  8. Total Cholesterol

    Fasting total cholesterol level is measured in serum in mg/dL

    Measured: Change from baseline at 12 months

  9. Anti-Nuclear Antibodies (ANA)

    ANA is measured as a titer by serum dilution detects autoimmune disease.

    Measured: Change from baseline at 12 months

  10. 25-hydroxy (OH) Vitamin D3

    25-OH Vitamin D3 is measured in blood in nanogram/milliLiter (ng/mL) detects deficiencies.

    Measured: Change from baseline at 12 months

  11. High sensitivity C-Reactive Protein (Hs-CRP)

    Hs-CRP is measured in blood in mg/L detects inflammation.

    Measured: Change from baseline at 12 months

  12. Homocysteine

    Homocysteine is measured in serum in micromol/Liter (µmol/L)

    Measured: Change from baseline at 12 months

  13. Omega-3 Fatty Acids

    Omega-3 fatty acids: Eicosapentaenoic (EPA), Docosahexaenoic (DHA), and Docosapentaenoic (DPA) levels are measured in % weight.

    Measured: Change from baseline at 12 months

  14. Beck Depression Inventory (BDI)

    BDI is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Rating system: 1-10: These ups and downs are considered normal; 11-16: Mild mood disturbance; 17-20: Borderline clinical depression; 21-30: Severe depression; over 40: Extreme depression

    Measured: Change from baseline at 12 months

  15. Beck Anxiety Inventory (BAI)

    BAI is a multiple-choice self-report inventory that is used for measuring the severity of anxiety in children and adults.The BAI contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely). Higher total scores indicate more severe anxiety symptoms. The standardized cutoffs[4] are:

    0-7: minimal anxiety 8-15: mild anxiety 16-25: moderate anxiety 26-63: severe anxiety

    Measured: Change from baseline at12 months

  16. Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Test

    PROMIS Sleep Disturbance Test is a self-scored test to identify sleep disturbance. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of sleep disturbance. The T-scores are interpreted as follows: Less than 55 = None to slight 55.0-59.9 = Mild 60.0-69.9 = Moderate 70 and over = Severe

    Measured: Change from baseline at 12 months

  17. Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Test

    PROMIS Anxiety test is a 7-item questionnaire that assesses the pure domain of anxiety in individuals age 18 and older. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 7 to 35 with higher scores indicating greater severity of anxiety. The T-scores are interpreted as follows: Less than 55 = None to slight 55.0-59.9 = Mild 60.0-69.9 = Moderate 70 and over = Severe

    Measured: Change from baseline at12 months

  18. Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form (SF)

    PROMIS Depression SF is an 8-item questionnaire that assesses the pure domain of depression in individuals age 18 and older. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of depression.The T-scores are interpreted as follows: Less than 55 = None to slight 55.0-59.9 = Mild 60.0-69.9 = Moderate 70 and over = Severe

    Measured: Change from baseline at 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jul 2019
  2. Study start1 Sep 2018
  3. Primary completion31 Dec 2019
  4. Study completion31 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04005456
Sponsor's protocol ID
LIFEHOUSE-PLMC
Acronym
LIFE-HOUSE
Status last verified
Apr 2022
First submitted
15 Jun 2019
Last updated
30 Oct 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Supplements and/or medical foods, Behavioral change support program and Food plan in people with Health, Subjective and Gastrointestinal Dysfunction, run by Metagenics, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Medical Outcomes Study Short Form 36 (MOS SF-36) questionnaire (time frame: Change from baseline at 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in